LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

91.66 2.53

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

88.68

Max

92.2

Schlüsselkennzahlen
By Trading Economics
Einkommen	-8.1M -56M
Verkäufe	2.9M 60M
EPS	-0.83
Gewinnspanne	-92.559
Angestellte	414
EBITDA	-9.7M -52M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+52.27% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	301M 6.2B
Vorheriger Eröffnungskurs	89.13
Vorheriger Schlusskurs	91.66

Nachrichtenstimmung

By Acuity

68%

32%

295 / 344 Ranking in Healthcare

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Mai 2026, 21:33 UTC

Ergebnisse

Correction to Salesforce 1Q Sales, Profit Rise Article

27. Mai 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. Mai 2026, 20:18 UTC

Ergebnisse

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. Mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. Mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. Mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. Mai 2026, 21:29 UTC

Heiße Aktien

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. Mai 2026, 21:08 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. Mai 2026, 21:02 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. Mai 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. Mai 2026, 20:55 UTC

Ergebnisse

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Mai 2026, 20:48 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. Mai 2026, 20:45 UTC

Ergebnisse

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. Mai 2026, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Webster Financial Stockholders Approve Sale to Banco Santander

27. Mai 2026, 20:32 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. Mai 2026, 20:30 UTC

Ergebnisse

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. Mai 2026, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. Mai 2026, 20:22 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:16 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. Mai 2026, 20:13 UTC

Ergebnisse

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

52.27% Vorteil

12-Monats-Prognose

Durchschnitt 136.77 USD 52.27%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

295 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.